Compare VanEck Junior Gold Miners (GDXJ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Moderna, Inc. — how do they compare? VanEck Junior Gold Miners trades at $92.62, while Moderna, Inc. trades at $62.94 (market cap $27.09B). The key difference: Moderna, Inc. is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| GDXJ | MRNA | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $81.80 |
52-Week Low | $64.22 | $22.36 |
Market Cap | — | $27.09B |
Enterprise Value | — | $23.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ is trading at $92.16, down 6.31% over the past 24 hours amid bearish technical signals. The ETF shows weakness with moving averages indicating strong selling pressure while oscillators remain neutral. Recent news highlights GDXJ's underperformance compared to peers and questions about its small-cap exposure composition.
The outlook remains cautious with technical indicators favoring sellers and fundamental concerns about portfolio composition. Investment opportunities exist for contrarian investors betting on gold miner recovery, but risks include continued underperformance and market volatility. The bearish technical setup suggests near-term pressure may persist.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
